Pacific Point Advisors LLC Invests $1.02 Million in Eli Lilly and Company (NYSE:LLY)

Pacific Point Advisors LLC bought a new position in Eli Lilly and Company (NYSE:LLY - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 1,235 shares of the company's stock, valued at approximately $1,020,000.

Several other institutional investors have also recently made changes to their positions in the company. Wick Capital Partners LLC lifted its holdings in shares of Eli Lilly and Company by 21.1% in the 4th quarter. Wick Capital Partners LLC now owns 471 shares of the company's stock worth $364,000 after acquiring an additional 82 shares during the last quarter. Vega Investment Solutions purchased a new position in Eli Lilly and Company in the 4th quarter worth about $186,000. Strait & Sound Wealth Management LLC increased its stake in Eli Lilly and Company by 5.5% in the 4th quarter. Strait & Sound Wealth Management LLC now owns 927 shares of the company's stock worth $716,000 after buying an additional 48 shares during the period. Helium Advisors LLC purchased a new position in Eli Lilly and Company in the 4th quarter worth about $531,000. Finally, BIP Alliance LLC purchased a new position in Eli Lilly and Company in the 4th quarter worth about $300,000. Institutional investors own 82.53% of the company's stock.

Wall Street Analyst Weigh In

LLY has been the topic of several recent analyst reports. Hsbc Global Res downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. Truist Financial raised their price target on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a "buy" rating in a research note on Monday, February 3rd. Guggenheim reaffirmed a "buy" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Wall Street Zen raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Friday, February 7th. Finally, Citigroup lowered their price target on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a research report on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eighteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $1,011.37.

Eli Lilly and Company Trading Down 1.4%

Shares of Eli Lilly and Company stock opened at $714.84 on Friday. The firm has a market capitalization of $677.48 billion, a PE ratio of 61.05, a P/E/G ratio of 1.40 and a beta of 0.48. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The firm's 50-day moving average price is $791.44 and its 200 day moving average price is $803.64. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The company had revenue of $12.73 billion during the quarter, compared to analysts' expectations of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The company's quarterly revenue was up 45.2% compared to the same quarter last year. During the same period in the prior year, the business posted $2.58 earnings per share. On average, sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be issued a $1.50 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a yield of 0.84%. Eli Lilly and Company's payout ratio is 48.82%.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. The trade was a 14.62% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.